Contribution of TLR4 and MyD88 for adjuvant monophosphoryl lipid A (MPLA) activity in a DNA prime-protein boost HIV-1 vaccine

Vaccine

Volumn 32, Issue 39, 2014, Pages 5049-5056

  Pouliot, Kimberly ^a   Buglione Corbett, Rachel ^b   Marty Roix, Robyn ^a   Montminy Paquette, Sara ^a   West, Kim ^b   Wang, Shixia ^b   Lu, Shan ^b   Lien, Egil ^a,c  

^a Division of Infectious Diseases and Immunology   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

Antibody response; DNA Prime protein boost vaccine; MPLA; MyD88; TLR4

Indexed keywords

GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN G; MYELOID DIFFERENTIATION FACTOR 88; PLASMID VECTOR; QS 21; TOLL LIKE RECEPTOR 4; ALUMINUM HYDROXIDE; CYTOKINE; DNA VACCINE; GP120 PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; IMMUNOLOGICAL ADJUVANT; LIPID A; MYD88 PROTEIN, MOUSE; PHOSPHORYL LIPID A; SAPONIN; TLR4 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE RESPONSE; DRUG ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOGLOBULIN BLOOD LEVEL; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNIZATION; IMMUNOLOGICAL MEMORY; IMMUNOLOGY;

ADJUVANTS, IMMUNOLOGIC; AIDS VACCINES; ALUMINUM HYDROXIDE; ANIMALS; CYTOKINES; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV-1; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN G; IMMUNOLOGIC MEMORY; LIPID A; MICE; MYELOID DIFFERENTIATION FACTOR 88; SAPONINS; T-LYMPHOCYTES; TOLL-LIKE RECEPTOR 4; VACCINES, DNA;

EID: 84906083428     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.07.010     Document Type: Article

References (46)

1. Tritto E., Mosca F., De Gregorio E. Mechanism of action of licensed vaccine adjuvants. Vaccine 2009, 27(25-26):3331-3334.
2. Guy B. The perfect mix: recent progress in adjuvant research. Nat Rev Microbiol 2007, 5(7):505-517.
3. Marrack P., McKee A.S., Munks M.W. Towards an understanding of the adjuvant action of aluminium. Nat Rev Immunol 2009, 9(4):287-293.
4. Flach TL, et al. Alum interaction with dendritic cell membrane lipids is essential for its adjuvanticity. Nat Med 2011; 17(4):479-87.
5. Kool M., et al. Cutting edge: alum adjuvant stimulates inflammatory dendritic cells through activation of the NALP3 inflammasome. J Immunol 2008, 181(6):3755-3759.
6. McKee A.S., et al. Alum induces innate immune responses through macrophage and mast cell sensors: but these sensors are not required for alum to act as an adjuvant for specific immunity. J Immunol 2009, 183(7):4403-4414.
7. Sharp F.A., et al. Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome. Proc Nat Acad Sci USA 2009, 106(3):870-875.
8. Ghimire TR, et al. Alum increases antigen uptake, reduces antigen degradation and sustains antigen presentation by DCs in vitro. Immunol Lett 2012; 147(1-2):55-62.
9. Mori A, et al. The vaccine adjuvant alum inhibits IL-12 by promoting PI3 kinase signaling while chitosan does not inhibit IL-12 and enhances Th1 and Th17 responses. Eur J Immunol 2012; 42(10):2709-19.
10. Eisenbarth S.C., et al. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 2008, 453(7198):1122-1126.
11. Ribi E. Beneficial modification of the endotoxin molecule. J Biol Response Mod 1984, 3(1):1-9.
12. Ribi E., et al. Lipid A and immunotherapy. Rev Infect Dis 1984, 6(4):567-572.
13. Thompson B.S., et al. The low-toxicity versions of LPS: MPL adjuvant and RC529, are efficient adjuvants for CD4+ T cells. J Leukocyte Biol 2005, 78(6):1273-1280.
14. Alving C.R., Rao M. Lipid A and liposomes containing lipid A as antigens and adjuvants. Vaccine 2008, 26(24):3036-3045.
15. Kolanowski ST, et al. TLR4-mediated pro-inflammatory dendritic cell differentiation in humans requires the combined action of MyD88 and TRIF. Innate Immun. 2014; 20(4): 423-30.
16. Chilton PM, et al. Adjuvant activity of naturally occurring monophosphoryl lipopolysaccharide preparations from mucosa-associated bacteria. Infect Immun 2013; 81(9):3317-25.
17. Mata-Haro V., et al. The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science 2007, 316(5831):1628-1632.
18. Cekic C., et al. Selective activation of the p38 MAPK pathway by synthetic monophosphoryl lipid A. J Biol Chem 2009, 284(46):31982-31991.
19. Behboudi S., Morein B., Villacres-Eriksson M. In vivo and in vitro induction of IL-6 by Quillaja saponaria molina triterpenoid formulations. Cytokine 1997, 9(9):682-687.
20. den Brok MH, et al. Saponin-based adjuvants create a highly effective anti-tumor vaccine when combined with in situ tumor destruction. Vaccine 2012; 30(4):737-44.
21. Cristillo A.D., et al. Preclinical evaluation of cellular immune responses elicited by a polyvalent DNA prime/protein boost HIV-1 vaccine. Virology 2006, 346(1):151-168.
22. Agnandji ST, et al. A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N Engl J Med 2012; 367(24):2284-95.
23. Agnandji ST, et al. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med 2011; 365(20):1863-75.
24. Bejon P., et al. Efficacy of RTS,S malaria vaccines: individual-participant pooled analysis of phase 2 data. Lancet Infect Dis 2013, 13(4):319-327.
25. Pal R., et al. Immunization of rhesus macaques with a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype. Virology 2006, 348(2):341-353.
26. Pal R., et al. Polyvalent DNA prime and envelope protein boost HIV-1 vaccine elicits humoral and cellular responses and controls plasma viremia in rhesus macaques following rectal challenge with an R5 SHIV isolate. J Med Primatol 2005, 34(5-6):226-236.
27. Wang S., et al. Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers. Vaccine 2008, 26(31):3947-3957.
28. Bansal A., et al. Multifunctional T-cell characteristics induced by a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine regimen given to healthy adults are dependent on the route and dose of administration. J Virol 2008, 82(13):6458-6469.
29. Kennedy J.S., et al. The safety and tolerability of an HIV-1 DNA prime-protein boost vaccine (DP6-001) in healthy adult volunteers. Vaccine 2008, 26(35):4420-4424.
30. Buglione-Corbett R., et al. Serum cytokine profiles associated with specific adjuvants used in a DNA prime-protein boost vaccination strategy. PLoS One 2013; 8(9):e74820.
31. Meng J., Lien E., Golenbock D.T. MD-2-mediated ionic interactions between lipid A and TLR4 are essential for receptor activation. J Biol Chem 2010, 285(12):8695-8702.
32. Ohto U., et al. Structural basis of species-specific endotoxin sensing by innate immune receptor TLR4/MD-2. Proc Nat Acad Sci USA 2012, 109(19):7421-7426.
33. Hajjar A.M., et al. Humanized TLR4/MD-2 mice reveal LPS recognition differentially impacts susceptibility to Yersinia pestis and Salmonella enterica. PLoS Pathog 2012, 8(10):e1002963.
34. Casella C.R., Mitchell T.C. Inefficient TLR4/MD-2 heterotetramerization by monophosphoryl lipid A. PLoS One 2013, 8(4):e62622.
35. Tanimura N, et al. The attenuated inflammation of MPL is due to the lack of CD14-dependent tight dimerization of the TLR4/MD2 complex at the plasma membrane. Int Immunol 2014; 26(6):307-14.
36. Park B.S., et al. The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature 2009, 458(7242):1191-1195.
37. Kagan J.C., et al. TRAM couples endocytosis of Toll-like receptor 4 to the induction of interferon-beta. Nat Immunol 2008, 9(4):361-368.
38. Xu Y., et al. Toll-like receptor 4 is a sensor for autophagy associated with innate immunity. Immunity 2007, 27(1):135-144.
39. Schmid D., Munz C. Innate and adaptive immunity through autophagy. Immunity 2007, 27(1):11-21.
40. Gandhapudi SK, Chilton PM, Mitchell TC, TRIF is required for TLR4 mediated adjuvant effects on T cell clonal expansion. PLoS One 2013; 8(2):e56855.
41. Hoebe K., et al. Upregulation of costimulatory molecules induced by lipopolysaccharide and double-stranded RNA occurs by Trif-dependent and Trif-independent pathways. Nat Immunol 2003, 4(12):1223-1229.
42. Meerak J., Wanichwecharungruang S.P., Palaga T. Enhancement of immune response to a DNA vaccine against Mycobacterium tuberculosis Ag85B by incorporation of an autophagy inducing system. Vaccine 2013, 31(5):784-790.
43. Adachi O., et al. Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity 1998, 9(1):143-150.
44. Hoshino K., et al. Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J Immunol 1999, 162(7):3749-3752.
45. Vaine M., et al. Antibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidity. Vaccine 2010, 28(17):2999-3007.
46. Brown L.E., et al. Synthetic peptides representing sequences within gp41 of HIV as immunogens for murine T- and B-cell responses. Arch Virol 1995, 140(4):635-654.